Form D · Other Technology
Strategikon Pharma, Inc.
San Francisco, CA · CIK 0001722200
Offering snapshot reported Nov 21, 2025 · SEC filing
- Reported sold
- $2.29M Offering amount: $3M
- Investors reported
- 15 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 8, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 21, 2025 | Initial | $2,291,885 | No comparison | 15 | SEC filing |
| Apr 6, 2018 | Initial | Yet to sell | No comparison | 0 | SEC filing |
| Nov 15, 2017 | Initial | Yet to sell | No comparison | 0 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-564718
Source: Form D, filed Nov 21, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Debra Apruzzese | Director |
| Paulo Carvalho | Executive |
| Chris Codeanne | Director |
| Anca Copaescu | Director, Executive |
| Mark Di Ianni | Director, Executive, Promoter |
| Rob Hess | Director |
| Nathanael Lentz | Director |
| Vincent Lepreux | Director |
| Mark Weinstein | Director, Executive |
Issuer details
Industry: Other Technology (See others in industry)
Address:
1 Sansome Street, 35th Floor Pmb #40621
San Francisco, CA, 94104
San Francisco, CA, 94104